La Jolla: Corporate Presentation (La Jolla) - Mar 14, 2015 - “Time Course of Activity Consistent with MoA, Effficacy Endpoint Also Met at End of Study Time Point (5 Weeks post Last Dose)”; “Phase 2a Predefined Analyses, Diabetic Subset Shows Most Improvement”;”Safety Data Summary”; “No Early Terminations at the 1.5 mg/m2 dose, 117 of 121 patients enrolled completed the study, Placebo: 40/41 completed; 1 withdrew consent after the first dose, 1.5 mg/m2 41/41 completed, 30 mg/m2: 36/39 completed; 1 withdrew consent before the first dose, 1 withdrew consent after the second dose due to scheduling conflict, 1 subject failed to come back after the 6th dose without explanation”; “No Grade 3 or 4 adverse events at the 1.5 mg/m2 dose, Similar event rate and profile among the groups, more grade 3/4 events in the 30 mg/m2 group”; “No Serious Adverse Events at the 1.5 mg/m2 dose”
P2a data • Chronic Kidney Disease • Renal Disease
|